Latest Thalidomide Stories
BURLINGTON, Mass., Dec.
WHITE PLAINS, N.Y. and CHAPPAQUA, N.Y., Nov. 30, 2010 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and BioTheryX, Inc.
BURLINGTON, Mass., Sept.
EMERYVILLE, Calif., July 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 5 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced interim results from an ongoing Phase 2 study, known as the 004 study.
EMERYVILLE, Calif., June 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
Norwegian researchers say that pregnant women are three times more likely to suffer from severe morning sickness if their mothers did.
WASHINGTON, April 1 /PRNewswire-USNewswire/ -- Two years after the Food and Drug Administration Amendments Act of 2007 (FDAAA) gave FDA new powers to require Risk Evaluation and Mitigation Strategies (REMS) for higher risk drugs and biologics, a new report concludes that an optimal future for REMS is possible if the agency adopts a systems approach when designing REMS programs and takes advantage of new technologies -- from electronic medical records to genetic testing -- that are changing...
WALTHAM, Mass., March 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the multiple myeloma drug market will more than double from $2.1 billion in 2008 to $5.3 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor 2010 findings from the topic entitled Multiple Myeloma reveal that market growth will be driven by increased use of Celgene's...
Trial conducted pursuant to Special Protocol Assessment with the Food and Drug Administration QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.